Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Excedrin Migraine

This article was originally published in The Tan Sheet

Executive Summary

Jackie Zeman, actress on daytime TV's General Hospital and a "migraine sufferer," is featured in Bristol-Myers Squibb's new TV ad for the migraine treatment, which began running Jan. 30. Excedrin Migraine "gives me the strong, fast relief I need," she says, as the superimposed message "For mild to moderate pain" appears on the screen. "My doctor says it's the only nonprescription medicine that's FDA-approved for migraine pain relief. So the migraine pain goes away and I can get back to work, because the show must go on." Excedrin Migraine ads previously pointed out the product's formula is identical with Extra Strength Excedrin, which was criticized in a warning letter from FDA ("The Tan Sheet" June 15, 1998, p. 1)

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts